OnBioVC

NeuroPhage Pharmaceuticals, Inc.: Series B $9M

arubenstein — Mon, 28 May 2012 22:25:56 PDT

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

Jiff, Inc.: Series A $7.5M

arubenstein — Mon, 28 May 2012 22:18:46 PDT

Jiff (Palo Alto, CA) a commercial-stage health IT company focused on a HIPAA-compliant private healthcare social network and digital health application platform, closed a $7.5M Series A financing. Participants include Aeris Capital and Aberdare Ventures.

ViewRay, Inc.: Series C $26.3M

arubenstein — Mon, 28 May 2012 22:14:36 PDT

ViewRay (Oakwood Village, OH) a clinical-stage medical device company focused on MRI-guided radiation therapy system for the treatment of various cancers, closed a $26.3M Series C financing, bringing the total round to $45M. Participants include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed and Siemens Venture Capital.

Tarsa Therapeutics, Inc.: Series B $28M

arubenstein — Mon, 28 May 2012 22:07:54 PDT

Tarsa Therapeutics (Philadelphia, PA) a clinical-stage biopharmaceutical company focused on treatments for postmenopausal osteoporosis, closed a $28 Series B financing. Participants include Foresite Capital, Novo, MVM Life Science Partners and Quaker Partners.

CardioInsight Technologies, Inc.: Series C $7.5M

arubenstein — Mon, 28 May 2012 22:00:51 PDT

CardioInsight Technologies (Cleveland, OH) a commercial-stage medical device company focused on non-invasive electrocardiographic mapping technology, closed a $7.5 Series C financing. Participants were not disclosed.

BiO2 Medical, Inc.: Series B $13.7M

arubenstein — Mon, 28 May 2012 21:54:28 PDT

BiO2 Medical (San Antonio, TX) a clinical-stage medical device company focused on catheters for pulmonary embolism in critical care patients, closed a $13.7M Series B financing. Participants include Incyte Capital and Pasadera Capital.

ImaginAb, Inc.: Series A $12.5M

arubenstein — Mon, 28 May 2012 21:49:21 PDT

ImaginAb (Inglewood, CA) a clinical-stage biopharmaceutical company focused on re-engineered therapeutic antibody fragments against biologic targets for diagnostic imaging with Positron Emission Tomography scans for management of cancer and autoimmune disease, closed a $12.5M Series B financing. Participants include Novartis Venture Funds, Merieux Developpement, Nextech Invest, Cycad Group and Momentum Biosciences.

Relievant Medsystems, Inc.: Series D $30M

arubenstein — Mon, 28 May 2012 21:28:59 PDT

Relievant Medsystems (Redwood City, CA) a clinical-stage medical device company focused on a device for radio frequency nerve ablation for chronic axial low back pain, closed a $30M Series D financing. Participants include New Enterprise Associates, Morgenthaler Ventures, Emergent Medical Partners, Canaan Partners and Onset Ventures.

Genalyte, Inc.: Series A $11.8M

arubenstein — Mon, 28 May 2012 21:09:52 PDT

Genalyte (San Diego, CA) a clinical-stage medical device company focused on next-generation multiplexing technology, hardware and software for antibody, protein and nucleic acid assays for autoimmune diseases and other diseases, closed a $11.8M Series A financing. Participants include Redmile Group and Claremont Creek Ventures.

Stemgent, Inc.: Series C $6.3M

arubenstein — Mon, 28 May 2012 21:07:16 PDT

Stemgent (Cambridge, MA) a commercial-stage biopharmaceutical company focused on stem cell reagents and tools for stem cell researchers, closed a $6.3M Series C financing. Participants include HealthCare Ventures and Morganthaler Partners.

Phosphate Therapeutics, Ltd.: Series A $13.8M

arubenstein — Sun, 20 May 2012 22:14:05 PDT

Phosphate Therapeutics (London, United Kingdom) a clinical-stage biopharmaceutical company focused on small molecules phosphate binders for hyperphosphatemia and renal failure, closed a $13.8M Series A financing. Participants include Inventages Venture Capital.

S.E.A. Medical Systems, Inc.: Series B $3M

arubenstein — Sun, 20 May 2012 22:08:28 PDT

S.E.A. Medical Systems (Santa Clara, CA) a development-stage medical device company focused on IV drug, concentration and diluent monitoring devices for safety and prevention of drug errors, closed a $3M Series B financing. Participants include JK&B Capital.

Mevion Medical Systems, Inc.: Series G $45M

arubenstein — Sun, 20 May 2012 22:06:16 PDT

Mevion Medical Systems (Littleton, MA) a commercial-stage medical device company focused on proton beam radiotherapy device for cancer, closed a $45M Series G financing. Participants include ProQuest Investment, Caxton Heath Life Sciences, Venrock and CHL Medical Partners.